InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: antihama post# 2440

Friday, 01/11/2019 2:11:23 PM

Friday, January 11, 2019 2:11:23 PM

Post# of 3283
I hope MDACC presents some combo data. That could be very exciting. I think they are focused on Bevicizumab + Pozi.

I'm not too sure I want to see more EGFRexon20 data since I think it is compromised by the logistics of patient treatment and access.

I think MDACC stopped the HER2 study to funnel patients into Zenith20 cohort.